Matching articles for "anemia"

Imetelstat (Rytelo) for Myelodysplastic Syndromes (online only)

   
The Medical Letter on Drugs and Therapeutics • September 30, 2024;  (Issue 1712)
The FDA has approved imetelstat (Rytelo – Geron), a first-in-class telomerase inhibitor, for treatment of low- to intermediate-1 risk myelodysplastic syndromes (MDS) in adults with...
The FDA has approved imetelstat (Rytelo – Geron), a first-in-class telomerase inhibitor, for treatment of low- to intermediate-1 risk myelodysplastic syndromes (MDS) in adults with transfusion-dependent anemia requiring 4 or more red blood cell (RBC) units over 8 weeks who have not responded to, are no longer responding to, or are ineligible for erythropoiesis-stimulating agents (ESAs).
Med Lett Drugs Ther. 2024 Sep 30;66(1712):e169-70 | Show Full IntroductionHide Full Introduction

Daprodustat (Jesduvroq) for Anemia of Chronic Kidney Disease

   
The Medical Letter on Drugs and Therapeutics • February 19, 2024;  (Issue 1696)
The FDA has approved daprodustat (Jesduvroq – GSK), a hypoxia-inducible factor prolyl hydroxylase inhibitor (HIF-PHI), for oral treatment of anemia due to chronic kidney disease (CKD) in adults who...
The FDA has approved daprodustat (Jesduvroq – GSK), a hypoxia-inducible factor prolyl hydroxylase inhibitor (HIF-PHI), for oral treatment of anemia due to chronic kidney disease (CKD) in adults who have been on dialysis for at least 4 months. It is the first HIF-PHI and the first oral drug to be approved in the US for this indication.
Med Lett Drugs Ther. 2024 Feb 19;66(1696):25-7 | Show Full IntroductionHide Full Introduction

Ferric Carboxymaltose (Injectafer) for Iron Deficiency Anemia

   
The Medical Letter on Drugs and Therapeutics • December 9, 2013;  (Issue 1431)
The FDA has approved ferric carboxymaltose (Injectafer – American Regent), a 2-dose intravenous iron replacement product, for treatment of iron deficiency anemia (IDA) in adults who cannot tolerate...
The FDA has approved ferric carboxymaltose (Injectafer – American Regent), a 2-dose intravenous iron replacement product, for treatment of iron deficiency anemia (IDA) in adults who cannot tolerate or have had an unsatisfactory response to oral iron and in those who have non-dialysis-dependent chronic kidney disease (CKD). It is the sixth IV iron product approved in the US.
Med Lett Drugs Ther. 2013 Dec 9;55(1431):99-100 | Show Full IntroductionHide Full Introduction

Peginesatide (Omontys) for Anemia in Chronic Kidney Disease

   
The Medical Letter on Drugs and Therapeutics • June 11, 2012;  (Issue 1392)
The FDA has approved the erythropoiesis-stimulating agent (ESA) peginesatide (Omontys – Affymax/Takeda), a synthetic peptide analog of erythropoietin, for treatment of anemia in patients with chronic...
The FDA has approved the erythropoiesis-stimulating agent (ESA) peginesatide (Omontys – Affymax/Takeda), a synthetic peptide analog of erythropoietin, for treatment of anemia in patients with chronic kidney disease (CKD) who are on dialysis. Peginesatide is the third ESA to become available in the US.Overuse of the other two, which have broader indications, has been a concern.
Med Lett Drugs Ther. 2012 Jun 11;54(1392):45-6 | Show Full IntroductionHide Full Introduction

Correction: Ferumoxytol (Feraheme)

   
The Medical Letter on Drugs and Therapeutics • April 19, 2010;  (Issue 1336)
In the Medical Letter article on Ferumoxytol (Feraheme) - A New Parenteral Iron Formulation (2010; 52:23), the last sentence of the Dosage, Administration and Cost paragraph should have listed the cost of 1...
In the Medical Letter article on Ferumoxytol (Feraheme) - A New Parenteral Iron Formulation (2010; 52:23), the last sentence of the Dosage, Administration and Cost paragraph should have listed the cost of 1 gram of sodium ferric gluconate (Ferrlecit) as about $600.
Med Lett Drugs Ther. 2010 Apr 19;52(1336):32 | Show Full IntroductionHide Full Introduction

Ferumoxytol (Feraheme) - A New Parenteral Iron Formulation

   
The Medical Letter on Drugs and Therapeutics • March 22, 2010;  (Issue 1334)
Ferumoxytol (Fer yoo mox’ i tole; Feraheme – AMAG), an intravenous (IV) iron replacement product, has been approved by the FDA for treatment of iron deficiency anemia in adults with chronic kidney disease....
Ferumoxytol (Fer yoo mox’ i tole; Feraheme – AMAG), an intravenous (IV) iron replacement product, has been approved by the FDA for treatment of iron deficiency anemia in adults with chronic kidney disease. Iron deficiency anemia is common in chronic kidney disease and may be associated with decreased absorption from the gastrointestinal tract, limiting the usefulness of oral iron replacement. IV iron replacement can lower the dose requirement for erythropoiesis-stimulating drugs, particularly in patients on dialysis
Med Lett Drugs Ther. 2010 Mar 22;52(1334):23-13 | Show Full IntroductionHide Full Introduction

Eculizumab (Soliris) for Paroxysmal Nocturnal Hemoglobinuria

   
The Medical Letter on Drugs and Therapeutics • September 24, 2007;  (Issue 1270)
Eculizumab (Soliris - Alexion) has been approved by the FDA for reduction of hemolysis in patients with paroxysmal nocturnal hemoglobinuria (PNH), a rare form of hemolytic anemia. A recombinant humanized...
Eculizumab (Soliris - Alexion) has been approved by the FDA for reduction of hemolysis in patients with paroxysmal nocturnal hemoglobinuria (PNH), a rare form of hemolytic anemia. A recombinant humanized monoclonal antibody, eculizumab is the first drug to be marketed for this indication.
Med Lett Drugs Ther. 2007 Sep 24;49(1270):79-80 | Show Full IntroductionHide Full Introduction

Erythropoietin Safety Concerns

   
The Medical Letter on Drugs and Therapeutics • May 7, 2007;  (Issue 1260)
The erythropoiesis-stimulating agents (ESAs) epoetin alfa (Epogen, Procrit) and darbepoetin alfa (Aranesp) are widely used for treatment of anemia and to reduce the need for red blood cell transfusions. Based...
The erythropoiesis-stimulating agents (ESAs) epoetin alfa (Epogen, Procrit) and darbepoetin alfa (Aranesp) are widely used for treatment of anemia and to reduce the need for red blood cell transfusions. Based on the results of recent clinical trials indicating an increased risk of serious adverse events and death associated with ESAs, particularly when used to achieve a hemoglobin concentration ≥12 g/dL, the FDA has revised the prescribing information for these drugs to include a black box warning.
Med Lett Drugs Ther. 2007 May 7;49(1260):37-9 | Show Full IntroductionHide Full Introduction

Deferasirox (Exjade): A New Iron Chelator

   
The Medical Letter on Drugs and Therapeutics • April 24, 2006;  (Issue 1233)
Deferasirox (Exjade - Novartis), an oral chelating agent, recently received accelerated approval from the FDA as an orphan drug for oral treatment of chronic iron overload due to blood transfusions...
Deferasirox (Exjade - Novartis), an oral chelating agent, recently received accelerated approval from the FDA as an orphan drug for oral treatment of chronic iron overload due to blood transfusions (transfusional hemosiderosis) in patients >2 years old. Deferasirox is a tridentate (2 molecules of deferasirox bind to one atom of iron) chelating agent with high affinity for iron. It has much lower affinity for zinc and copper.
Med Lett Drugs Ther. 2006 Apr 24;48(1233):35-6 | Show Full IntroductionHide Full Introduction

Lenalidomide (Revlimid) for Anemia of Myelodysplastic Syndrome

   
The Medical Letter on Drugs and Therapeutics • April 10, 2006;  (Issue 1232)
Lenalidomide (Revlimid - Celgene), a thalidomide analog, has been approved by the FDA for treatment of patients with transfusion-dependent anemia due to myelodysplastic syndrome (MDS) associated with a 5q...
Lenalidomide (Revlimid - Celgene), a thalidomide analog, has been approved by the FDA for treatment of patients with transfusion-dependent anemia due to myelodysplastic syndrome (MDS) associated with a 5q deletion cytogenetic abnormality and a low or low-intermediate risk of mortality and progression to leukemia (based on the International Prognostic Scoring System).
Med Lett Drugs Ther. 2006 Apr 10;48(1232):31-2 | Show Full IntroductionHide Full Introduction

Hemolysis From Ceftriaxone

   
The Medical Letter on Drugs and Therapeutics • November 25, 2002;  (Issue 1144)
Immune-mediated hemolysis is a rare adverse effect of second- and third-generation cephalosporins, especially cefotetan (Cefotan) (PA Arndt et al, Transfusion 1999; 39:1239). A recent report serves as a...
Immune-mediated hemolysis is a rare adverse effect of second- and third-generation cephalosporins, especially cefotetan (Cefotan) (PA Arndt et al, Transfusion 1999; 39:1239). A recent report serves as a reminder that life-threatening immune-mediated hemolysis rarely can follow administration of ceftriaxone (Rocephin), one of the most commonly used parenteral antibiotics in the US (A Citak et al, J Paediatr Child Health 2002; 38:209).
Med Lett Drugs Ther. 2002 Nov 25;44(1144):100-1 | Show Full IntroductionHide Full Introduction

Erythropoietin (Procrit; Epogen) Revisited

   
The Medical Letter on Drugs and Therapeutics • May 14, 2001;  (Issue 1104)
Use of epoetin alfa, a recombinant human erythropoietin, is being promoted directly to consumers in vague advertisements that promise renewed energy and improved work capacity. Epoetin is approved by the FDA...
Use of epoetin alfa, a recombinant human erythropoietin, is being promoted directly to consumers in vague advertisements that promise renewed energy and improved work capacity. Epoetin is approved by the FDA for treatment of anemia due to chronic renal failure, cancer chemotherapy or HIV treatment, and before elective non-cardiac surgery. It is also used illicitly by competitive athletes to increase their endurance.
Med Lett Drugs Ther. 2001 May 14;43(1104):40-1 | Show Full IntroductionHide Full Introduction

Erythropoietin For Anemia

   
The Medical Letter on Drugs and Therapeutics • September 22, 1989;  (Issue 801)
Production of erythropoietin, a glycoprotein hormone secreted mainly by the kidney, is often low in patients with chronic renal failure (JW Eschbach, Kidney Int, 35:134, 1989). The US Food and Drug...
Production of erythropoietin, a glycoprotein hormone secreted mainly by the kidney, is often low in patients with chronic renal failure (JW Eschbach, Kidney Int, 35:134, 1989). The US Food and Drug Administration recently approved marketing of epoetin alfa (Epogen - Amgen), a recombinant human erythropoietin, for treatment of anemia in such patients. Epoetin is commercially available in Europe as Eprex (Ortho), and Eprex is available from Ortho in the USA on an investigational basis for treatment of anemia related to AIDS. Epogen and Eprex are chemically identical.
Med Lett Drugs Ther. 1989 Sep 22;31(801):85-6 | Show Full IntroductionHide Full Introduction